文献速递白血病造血干细胞移植与细胞治疗

如何治疗费城染色体阳性急性淋巴细胞白血病

How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2018-11-15

该文综述费城染色体阳性急性淋巴细胞白血病的治疗策略,指出酪氨酸激酶抑制剂(TKI)已成为该病任何治疗方案的基石,尽管目前仍需依赖细胞毒化疗和异基因造血细胞移植以实现最佳长期结局,但随着更强效TKI、新药及微小/可测量残留病监测方法的引入,有望减少对移植和细胞毒化疗的依赖。

要点

  • TKI已确立为费城染色体阳性急性淋巴细胞白血病任何治疗策略的基石。
  • 目前仍需依赖细胞毒化疗方案和异基因造血细胞移植以实现最佳长期结局。
  • 更强效TKI、新药及微小/可测量残留病监测的引入有望减少对移植和细胞毒化疗的依赖。

核心结论

  • 随着更强效TKI和其他新药以及更好的微小/可测量残留病监测方法的引入,我们正进入一个希望减少对该病移植和细胞毒化疗依赖的时代。

研究设计与样本

  • 原文未报告检索范围。

主要发现

  • 在费城染色体阳性急性淋巴细胞白血病中,越来越强效的酪氨酸激酶抑制剂(TKI)的引入已彻底改变治疗。
  • 这些药物已确立为该病任何治疗策略的基石,多项试验更好地定义了将其纳入既定范式的最佳方式。
  • 尽管使用TKI,我们仍继续依赖细胞毒化疗方案和异基因造血细胞移植以实现最佳长期结局。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of agents targeted at specific molecular events is changing the treatment paradigms in a number of malignancies. Historically, we have relied entirely on DNA-interactive, cytotoxic drugs for treating patients with leukemia. Increased understanding of the leukemic cell biology and pathogenesis, and the ways they evade the immune surveillance mechanisms, will likely lead to the development of more effective agents, and regimens less reliant on chemotherapy, able to achieve deep levels of disease eradication. In Philadelphia chromosome-positive acute lymphoblastic leukemia, the introduction of increasingly potent tyrosine kinas inhibitors (TKIs) has revolutionized therapy. These drugs have been established as the cornerstone of any therapeutic strategy in this disease, and a number of trials have better defined the best ways to incorporate them into the established paradigms. Despite using TKIs, we have continued to remain reliant on cytotoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-term outcomes. However, with the introduction of more potent TKIs and other novel agents, as well as better methods for monitoring minimal/measurable residual disease, we are entering an era where we hope to diminish our reliance on transplantation and cytotoxic chemotherapy in this disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ravandi F. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2018. PMID: 30442680. doi:10.1182/blood-2018-08-832105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。